<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> both alone and in combination with chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>